Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Phase 2 Interventional

Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder

NCT00026585
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Tamoxifen
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 6:13 PM EDT
Terminated Phase 2 Interventional Results available

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

NCT02156076
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
BMS-919373, Placebo (Matching with BMS-919373)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Anaheim, California • Costa Mesa, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 27, 2026, 6:13 PM EDT
Active, not recruiting Phase 1 Interventional

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

NCT04061746
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mesenchymal Stem Cells (MSCs), Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 27, 2026, 6:13 PM EDT
Not yet recruiting Phase 2 Interventional

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

NCT07528690
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Microbiota transplant therapy (MTT) capsules, Placebo capsule
Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
West Haven, Connecticut • Dallas, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 27, 2026, 6:13 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Aging, Beta Blockers, and Thermoregulatory Responses

NCT06582680
View directory record Official record
Conditions
Heat Stress, Aging
Interventions
Ambient Heat
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

NCT02094586
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
3,146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
19
States / cities
Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

NCT01516879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 27, 2026, 6:13 PM EDT
Not listed Phase 1 Interventional

Treating Stress and Anxiety in Individuals With Alcohol Use Disorder (AUD)

NCT06224127
View directory record Official record
Conditions
Anxiety Disorders, Alcohol Use Disorder, Stress, Psychological
Interventions
active heat, Active c tactile fiber stimulation, sham heat, Sham c tactile fiber stimulation
Device · Drug
Lead sponsor
Soovu Labs Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 4 Interventional

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial

NCT02462590
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea, Diarrhea
Interventions
L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glucosamine and Chondroitin in Preventing Inflammation in Overweight Patients

NCT03827161
View directory record Official record
Conditions
Healthy Subject, Overweight
Interventions
Glucosamine, Placebo
Dietary Supplement · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
20 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00722358
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Orlando, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

NCT03897348
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Lacosamide 100 mg, Lacosamide 200 mg
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

NCT01215149
View directory record Official record
Conditions
HIV Infections
Interventions
Ad35-ENV vaccine, Ad26.ENVA.01 vaccine, Placebo Control
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IVIG (Gamunex-C) Treatment Study for POTS Subjects

NCT03919773
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
IVIG, Albumin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

NCT01983241
View directory record Official record
Conditions
Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions
Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staged Phase I/II Hepatitis C Prophylactic Vaccine

NCT01436357
View directory record Official record
Conditions
Hepatitis C
Interventions
AdCh3NSmut1, MVA-NSmut, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 27, 2026, 6:13 PM EDT
Not listed Not applicable Interventional

Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers

NCT00446472
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Regranex®, Hydrogel
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Long Beach, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2010 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01515137
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Erlotinib, Erlotinib plus sulindac, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
PF-05221304 Monotherapy, PF-06865571 Monotherapy, Placebo, PF-05221304 and PF-06865571 Combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
29
States / cities
Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 27, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

NCT02993237
View directory record Official record
Conditions
HIV-1
Interventions
DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 27, 2026, 6:13 PM EDT